Citi analyst Amit Hazan raised his price target for Varian Medical Systems to $145 and keeps a Buy rating on the shares. China posted medical equipment plans through 2020 which include new linear accelerators of nearly 1,400 total units, Hazan tells investors in a research note. He views this as a "major positive" for radiation oncology players and that "far exceeds expectations." Inclusive in the quota are 188 Class A and 1,208 Class B systems, and Varian "is better positioned than ever before to capture both ends of the quality spectrum," Hazan writes.